Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

Abera Bioscience

6.40 SEK

-2.29 %

Less than 1K followers

ABERA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.29 %
+10.34 %
-5.88 %
-5.88 %
-2.29 %
+9.97 %
+16.36 %
-39.05 %
-42.08 %

Abera Bioscience is a Swedish biotechnology company that develops nasal vaccines based on a proprietary OMV-based platform technology. The company's focus is on nasal vaccines that provide immune responses in both mucosal and systemic areas. Abera develops vaccines against several respiratory infectious diseases, including pneumococci, influenza and pandemic preparedness, with projects in preclinical and planned clinical phases. The company was founded in 2012 and is headquartered in Uppsala.

Read more
Market cap
131.19M SEK
Turnover
53.71K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/5
2026

Interim report Q1'26

10/6
2026

General meeting '26

20/8
2026

Interim report Q2'26

All
Press releases
ShowingAll content types
Press release4/1/2026, 6:25 AM

Abera Bioscience: Ny publikation i npj Vaccines ger viktig insikt i verkningsmekanismen för Aberas pneumokockvaccin Ab-01.12

Abera Bioscience
Press release3/11/2026, 12:07 PM

Abera Bioscience publicerar presentation från Aktiespararnas Stora Aktiedagarna

Abera Bioscience
Regulatory press release2/12/2026, 7:30 AM

Abera Bioscience AB Bokslutskommuniké 2025

Abera Bioscience

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/10/2026, 7:20 AM

Abera Bioscience: Brev från Aberas nya storägare

Abera Bioscience
Regulatory press release2/3/2026, 12:36 PM

Abera Bioscience inleder nya studier inom pandemisk influensa - CEPI godkänner förlängning av projekt

Abera Bioscience
Regulatory press release1/30/2026, 8:56 AM

Abera Bioscience stärker kapitalbasen för accelererad utveckling och breddad pipeline

Abera Bioscience
Press release1/27/2026, 12:26 PM

Abera Bioscience publicerar presentation från Aktiespararnas life science event

Abera Bioscience
Press release1/22/2026, 10:21 AM

Abera Bioscience stärker teamet för att möta högt utvecklingstempo

Abera Bioscience
Press release11/27/2025, 1:03 PM

Abera Bioscience publicerar presentation från FS Markets investerarevent i Stockholm

Abera Bioscience
Regulatory press release11/13/2025, 7:01 AM

Abera Bioscience AB Delårsrapport Q3 2025

Abera Bioscience
Press release11/4/2025, 7:30 AM

Abera Bioscience: Artikel: Influensa och kampen mot framtida pandemier

Abera Bioscience
Press release10/21/2025, 8:18 AM

Abera Bioscience visar lovande långtidsdata för nasalt influensavaccin - starka och långvariga immunsvar i ny preklinisk studie

Abera Bioscience
Regulatory press release9/29/2025, 12:35 PM

Abera Bioscience tilldelas ca 880 000 SEK i bidrag från BactiVac för studier på sprayapplikator inför kliniska prövningar av pneumokockvaccin Ab-01.12

Abera Bioscience
Press release9/8/2025, 7:25 AM

Abera Bioscience: Artikel: Pneumokocker och vaccin - en kamp mot en mångfacetterad bakterie

Abera Bioscience
Regulatory press release8/21/2025, 6:02 AM

Abera Bioscience AB Delårsrapport Q2 2025

Abera Bioscience
Regulatory press release8/18/2025, 8:38 AM

Abera Bioscience offentliggör utfall i riktad emission - emissionen fulltecknad

Abera Bioscience
Regulatory press release7/22/2025, 7:02 AM

Abera Bioscience tilldelas ytterligare 4,7 MSEK från CEPI för utökad utveckling av nasal influensavaccinkandidat

Abera Bioscience
Regulatory press release7/17/2025, 7:48 AM

Abera Bioscience genomför riktad emission av units för att finansiera klinisk fas I-studie av pneumokockvaccinkandidaten Ab-01.12

Abera Bioscience
Press release6/24/2025, 11:21 AM

Abera Bioscience: Artikel: Nästa pandemi - varför vaccinet måste vara snabbare än viruset

Abera Bioscience
Regulatory press release6/11/2025, 12:37 PM

Kommuniké från årsstämma i Abera Bioscience AB

Abera Bioscience
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.